Halozyme Therapeutics, Inc.HALONASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 62% recommend buying.

Consensus Rating

Buy

21 analysts·High coverage

62%

Rating Distribution

Strong Buy

00%

Buy

1362%

Hold

838%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Current price is 4% above analyst consensus — near fair value expected.

Bear Case

$56.00

-27%

Consensus

$73.17

-4%

Bull Case

$92.00

+20%

Price Range21 analysts

Low

Consensus

High

$56.00

$92.00

Current Target

Current Price

$76.48

Above Target

$3.31

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$8.24(4 analysts)

P/E15x

Current: 15.1x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+12.14%

EPS+17.29%

FY2028

Rev+6.53%

EPS+7.56%

FY2029

Rev-7.77%

EPS-5.71%

Earnings Surprises

Beat rate:83%(10/12 quarters)

Avg surprise:+11.6%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 8, 2026Morgan Stanley

Halozyme price target lowered to $75 from $79 at Morgan Stanley

Target:$75.00

-0.1%from $75.11

Dec 4, 2025UBS

Halozyme downgraded to Sell from Neutral at Goldman Sachs

Target:$56.00

-13.4%from $64.66

Dec 4, 2025Goldman Sachs

Goldman Sachs Downgrades Halozyme Therapeutics (HALO) to Sell 'as we approach peak revenue'

Target:$56.00

-10.8%from $62.81

Nov 4, 2025JMP Securities

Halozyme price target raised to $92 from $91 at Citizens JMP

Target:$92.00

+39.0%from $66.20

Oct 20, 2025Morgan Stanley

Halozyme price target lowered to $79 from $80 at Morgan Stanley

Target:$79.00

+17.9%from $67.03

Oct 14, 2025Leerink Partners

Halozyme upgraded at Leerink on lower-than-feared Part B exposure

Target:$70.00

+5.0%from $66.65

Oct 2, 2025H.C. Wainwright

Halozyme price target raised to $90 from $85 at H.C. Wainwright

Target:$90.00

+20.1%from $74.94

May 14, 2025Morgan Stanley

Halozyme downgraded to Equal Weight from Overweight at Morgan Stanley

Target:$62.00

-6.9%from $66.58

Nov 15, 2024Piper Sandler

Piper Sandler Reiterates Neutral Rating on Halozyme Therapeutics (HALO)

Target:$52.00

+11.3%from $46.72

Jun 7, 2024H.C. Wainwright

Halozyme Therapeutics (HALO) PT Raised to $65 at H.C. Wainwright

Target:$65.00

+26.4%from $51.44

Jun 7, 2024Piper Sandler

Halozyme downgraded to Neutral after rally at Piper Sandler

Target:$51.00

-0.9%from $51.44

Jun 7, 2024Wells Fargo

Halozyme Therapeutics (HALO) PT Raised to $58 at Wells Fargo

Target:$58.00

+12.8%from $51.44

Jun 6, 2024Goldman Sachs

Halozyme price target raised to $44 from $41 at Goldman Sachs

Target:$44.00

-14.5%from $51.44

Jan 11, 2023Leerink Partners

SVB Leerink Maintains Outperform on Halozyme Therapeutics, Lowers Price Target to $61

Target:$61.00

+9.5%from $55.70

Dec 21, 2022Morgan Stanley

Morgan Stanley Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $65

Target:$65.00

+10.9%from $58.63

Nov 28, 2022Wells Fargo

Wells Fargo Initiates Coverage On Halozyme Therapeutics with Overweight Rating, Announces Price Target of $65

Target:$65.00

+17.0%from $55.53

Nov 22, 2022J.P. Morgan

JP Morgan Maintains Overweight on Halozyme Therapeutics, Raises Price Target to $54

Target:$54.00

+2.4%from $52.74

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance